Staphylococcus aureus accessory gene regulator (agr) group II: Is there a relationship to the development of intermediate-level glycopeptide resistance?

Journal of Infectious Diseases

Volumn 187, Issue 6, 2003, Pages 929-938

  Sakoulas, George ^a,c,e   Eliopoulos, George M ^a,c   Moellering Jr , Robert C ^a,c   Novick, Richard P ^d   Venkataraman, Lata ^b   Wennersten, Christine ^a   DeGirolami, Paola C ^b,c   Schwaber, Mitchell J ^a,c   Gold, Howard S ^a,c  

^a Perioperative and Pain Medicine   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Crystal Run Healthcare   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPEPTIDE; VANCOMYCIN;

AGR GENE; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIAL SURVIVAL; BACTERIUM ISOLATE; CONTROLLED STUDY; GENE CLUSTER; GENE LOCUS; GENETIC ENGINEERING; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; NUCLEOTIDE SEQUENCE; POPULATION GENETICS; PRIORITY JOURNAL; REGULATOR GENE; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; DRUG RESISTANCE, BACTERIAL; GENE DELETION; HUMANS; METHICILLIN; SIGNAL TRANSDUCTION; STAPHYLOCOCCUS AUREUS; TRANS-ACTIVATORS; VANCOMYCIN;

EID: 0037443852     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/368128     Document Type: Article

References (49)

1. Ji G, Beavis R, Novick RP. Bacterial interference caused by autoinducing peptide variants. Science 1997; 276:2027-30.
2. Lyon GJ, Mayville P, Muir TW, Novick RP. Rational design of a global inhibitor of the virulence response in Staphylococcus aureus, based in part on localization of the site of inhibition to the receptor-histidine kinase, AgrC. Proc Natl Acad Sci USA 2000; 97:13330-5.
3. Novick RP. Pathogenicity factors and their regulation. In: Fischett VA, Novick RP, Ferretti JJ, Portnoy DA, Rood JI, eds. Gram-positive pathogens. Washington, DC: American Society for Microbiology, 2000:392-407
4. Novick RP, Ross HF, Projan S, Kornblum J, Kreiswirth B, Moghazeh S. Synthesis of staphylococcal virulence factors is controlled by a regulatory RNA molecule. EMBO J 1993; 12:3967-75.
5. Dunman PM, Murphy E, Haney S, et al. Transcription profiling-based identification of Staphylococcus aureus genes regulated by the agr and/or sarA loci. J Bacteriol 2001; 183:7341-53.
6. Moore PCL, Lindsay JA. Genetic variation among hospital isolates of methicillin-sensitive Staphylococcus aureus: evidence for horizontal transfer of virulence genes. J Clin Microbiol 2001; 39:2760-7.
7. van Leeuwen W, van Nieuwenhuizen W, Gijzen C, Verbrugh H, van Belkum A. Population studies of methicillin-resistant and -sensitive Staphylococcus aureus strains reveal a lack of variability in the agrD gene, encoding a staphylococcal autoinducer peptide. J Bacteriol 2000; 182:5721-9.
8. Pearman JW. Community-acquired MRSA: the Australian experience [abstract 359]. In: Program and abstracts of the 10th International Symposium on Staphylococci and Staphylococcal Diseases (Tsukuba, Japan). Japan: Japan Symposium on Staphylococci and Staphylococcal Diseases, 2002:18.
9. Naimi TS. Community-acquired MRSA: the American experience [abstract 352]. In: Program and abstracts of the 10th International Symposium on Staphylococci and Staphylococcal Diseases (Tsukuba, Japan). Japan: Japan Symposium on Staphylococci and Staphylococcal Diseases, 2002:19.
10. Dufour P, Gillet Y, Bes M, et al. Community-acquired methicillin-resistant Staphylococcus aureus infections in France: emergence of a single clone that produces panton-valentine leukocidin. Clin Infect Dis 2002; 35:819-24.
11. Blevins JS, Beenken KE, Elasri MO, Hurlburt BK, Smeltzer MS. Strain-dependent differences in the regulatory roles of sarA and agr in Staphylococcus aureus. Infect Immun 2002; 70:470-80.
12. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40:135-6.
13. Kuroda M, Ohta T, Uchiyama I, et al. Whole genome sequencing of methicillin-resistant Staphylococcus aureus. Lancet 2001; 357:1225-40.
14. Sakoulas G, Eliopoulos GM, Moellering RC Jr, et al. Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Antimicrob Agents Chemother 2002; 46:1492-502.
15. r) of methicillin-resistant Staphylococcus aureus (MRSA) [abstract C1-1062]. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 2002:71.
16. Monk AB, Howe R, Enright MC. MLST analysis of glycopeptide intermediate susceptibility Staphylococcus aureus [abstract 300]. In: Program and abstracts of the 10th International Symposium on Staphylococci and Staphylococcal Diseases (Tsukuba, Japan). Japan: Japan Symposium on Staphylococci and Staphylococcal Diseases, 2002:150.
17. Enright MC, Robinson DA, Randle G, Feil EJ, Grundman H, Spratt BG. The evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA). Proc Natl Acad Sci USA 2002; 99:7687-92.
18. Sakoulas G, Gold HS, Venkataraman L, Degirolami PC, Eliopoulos GM, Qian Q. Methicittin-resistant Staphylococcus aureus: comparison of susceptibility testing methods and analysis of mecA-positive susceptible strains. J Clin Microbiol 2001; 39:3946-51.
19. Maslow J, Stutsky AM, Arbeit RD. The application of pulsed-field gel electrophoresis to molecular epidemiology. In: Persing DH, Smith TF, Tenover FC, White J, eds. Diagnostic molecular epidemiology: principles and applications. Washington, DC: American Society for Microbiology, 1993:563-72.
20. National Committee for Clinical Laboratory Standards (NCCLS). Methods for dilution antimicrobial susceptibility testing for bacteria that grow aerobically: approved standard. 5th ed. NCCLS document M7-A5. Wayne, PA: NCCLS, 2000:7-25.
21. Ince D, Hooper DC. Mechanisms and frequency of resistance to premafloxacin in Staphylococcus aureus: novel mutations suggest novel drug target interactions. Antimicrob Agents Chemother 2000; 44:3344-50.
22. Schmitz FJ, Fluit AC, Hafner D, et al. Development of resistance to ciprofloxacin, rifampin, and mupirocin in methicillin-susceptible and -resistant Staphylococcus aureus. Antimicrob Agents Chemother 2000; 44:3229-31.
23. Boyle-Vavra S, Carey RB, Daum RS. Development of vancomycin and lysostaphin resistance in a methicillin-resistant Staphylococcus aureus isolate. J Antimicrob Chemother 2001; 48:617-25.
24. Sieradzki K, Tomasz A. Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus. J Bacteriol 1997; 179:2557-66.
25. Fujimoto DF, Bayles KW. Opposing roles of the Staphylococcus aureus virulence regulators, agr and sar, in Triton X-100- and penicillin-induced autolysis. J Bacteriol 1998; 180: 3724-6.
26. Centers for Disease Control and Prevention. Staphylococcus aureus with reduced susceptibility to vancomycin: Illinois, 1999. MMWR Morb Mortal Wkly Rep 2000; 48:1165-7.
27. Geisel R, Schmitz FJ, Fluit AC, Labischinski H. Emergence, mechanism, and clinical implications of reduced glycopeptide susceptibility in Staphylococcus aureus. Eur J Clin Microbiol Infect Dis 2001; 20:685-97.
28. Tenover FC, Biddle JW, Lancaster MV. Increased resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg Infect Dis 2001; 7:327-32.
29. Avison MB, Bennett PM, Howe RA, Walsh TR. Preliminary analysis of the genetic basis for vancomycin resistance in Staphylococcus aureus strain Mu50. J Antimicrob Chemother 2002; 49:255-60.
30. Schaaff F, Reipert A, Bierbaum G. An elevated mutation frequency favors development of vancomycin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 2002; 46:3540-8.
31. Crisostomo MI, Westh H, Tomasz A, Chung M, Oliveira DC, de Lencastre H. The evolution of methicillin resistance in Staphylococcus aureus: similarity of genetic backgrounds in historically early methicillin-susceptible and -resistant isolates and contemporary epidemic clones. Proc Natl Acad Sci USA 2001; 98:9865-70.
32. Oliveira DC, Tomasz A, de Lencastre H. The evolution of pandemic clones of methicillin-resistant Staphylococcus aureus: identification of two ancestral backgrounds and the associated mec elements. Microb Drug Resist 2001; 7:349-61.
33. Weigel L. High-level vancomycin resistance in a clinical isolate of Staphylococcus aureus [abstract 111]. In: Program and abstracts of the 10th International Symposium on Staphylococci and Staphylococcal Diseases (Tsukuba, Japan). Japan: Japan Symposium on Staphylococci and Staphylococcal Diseases, 2002:16.
34. Centers for Disease Control and Prevention. Staphylococcus aureus resistant to vancomycin: United States, 2002. MMWR Morb Mortal Wkly Rep 2002; 51:565-7.
35. Strommenger B, Cuny C, Werner G, Witte W. Dynamics of epidemic MRSA in central Europe [abstract 215]. In: Program and abstracts of the 10th International Symposium on Staphylococci and Staphylococcal Diseases (Tsukuba, Japan). Japan: Japan Symposium on Staphylococci and Staphylococcal Diseases, 2002:102.
36. Shopsin B, Kreiswirth BN. Molecular epidemiology of methicillin-resistant Staphylococcus aureus. Emerg Infect Dis 2001; 7:323-6.
37. Moise-Broder PA, Sakoulas GM, Eliopoulos GM, Schentag JJ, Forrest A, Moellering RC Jr. Association of the accessory gene regulator specificity group II and response of methicillin-resistant Staphylococcus aureus infections to vancomycin [abstract C1-1059]. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 2002:70.
38. Ena J, Dick RW, Jones RN, Wenzel RP. The epidemiology of intravenous vancomycin usage in a university hospital: a 10-year study. JAMA 1993; 269:598-602.
39. Jarvis WR. Epidemiology, appropriateness, and cost of vancomycin use. Clin Infect Dis 1998; 26:1200-3.
40. Pallares R, Dick R, Wenzel RP, Adams JR, Nettleman MD. Trends in antimicrobial utilization at a tertiary teaching hospital during a 15-year period (1978-1992). Infect Control Hosp Epidemiol 1993; 14:376-82.
41. Cruciani M, Gatti G, Lazzarini L, et al. A study of vancomycin penetration in lung tissue of 30 patients at a university hospital in Italy. J Antimicrob Chemother 1996; 38:865-9.
42. Moellering RC Jr, Krogstad DJ, Greenblatt DJ. Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Ann Intern Med 1981; 94:343-6.
43. Hageman JC, Pegues D, Jepson C, et al. Vancomycin-intermediate Staphylococcus aureus in a home health-care patient. Emerg Infect Dis 2001; 7:1023-5.
44. Fekety R. Vancomycin and teicoplanin. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practices of infectious diseases. Philadelphia: Churchill Livingstone, 1995:346-54.
45. Cunha BA, Quintiliani R, Deglin JM, Izard MW, Nightingale CH. Pharmacokinetics of vancomycin in anuria. Rev Infect Dis 1981; 3(Suppl):S269-72.
46. De Bock V, Verbeelen D, Maes V, Sennesael J. Pharmacokinetics of vancomycin in patients undergoing hemodialysis and hemofiltration. Nephrol Dial Transplant 1989; 4:635-9.
47. Masur H, Fraancioli P, Ruddy M, Murray HW. Vancomycin serum levels and toxicity in chronic hemodialysis patients with Staphylococcus aureus bacteremia. Clin Nephrol 1983; 20:85-8.
48. DeSoi CA, Sahm DF, Umans JG. Vancomycin elimination during high-flux hemodialysis: kinetic model and comparison of four membranes. Am J Kid Dis 1992; 20:354-60.
49. Komatsuzawa H, Ohta K, Yamada S, Ehlert K, Labischinski H, Kajimura J, Fujiwara T, Sugai. Increased glycan chain length distribution and decreased susceptibility to moenomycin in a vancomycin-resistant Staphylococcus aureus mutant. Antimicrob Agents Chemother 2002; 46:75-81.